Lars Tönges

Professor of Neurology, Expert on #Parkinsons disease

[Lars Tönges @LarsToenges]

Please find our new internet presentation of our assembly of German #PD #networks now online: https://t.co/UfpoHJvEV2

[Lars Tönges @LarsToenges]

Please find our new publication on #Parkinsons and #autonomic dysfunction in @braincomms. Vagal atrophy in PD correlates with impairment of parasympathetic activity. Very nice collaborative work with colleagues from @ruhrunibochum. https://t.co/JihMAWYef0

[Lars Tönges @LarsToenges]

Please join our 3rd Symposium on #Parkinsons and other #movement_disorders @ St. Josef Hospital #Bochum on Sat Oct 29, 2022. Joint event of @ruhrunibochum and @NeuroEssen w key note speakers Prof. Klein @UniLuebeck Prof. Storch @unirostock. #neurogenetics https://t.co/jbuJ2FVVXh

[Lars Tönges @LarsToenges]

Please join our report about the 2022 Madrid #MDSCongress tonight at 6pm: https://t.co/vfQsFCIGsy. Lots of novel data about #Parkinsons and other movement disorder diseases. Presented together with Prof. Daniel Weiss from @uni_tue and Prof. Norbert Brüggemann from @UniLuebeck.

[Lars Tönges @LarsToenges]

Happy to have been able to contribute to the #SPARK Study for #Parkinsons, now published in @NEJM. There were high hopes for the antibody-based approaches, which unfortunately have failed. Novel trials target PwP and genetic risk - we do not give up !
https://t.co/uoQvRSMvQI

[Lars Tönges @LarsToenges]

Very good and comprehensive review about alpha-#Synuclein as a potential biomarker for #Parkinsons and other #synucleinopathies from @Hlashuel and @PedroJMagalhaes - very worth reading and open access ! 😉

[Lars Tönges @LarsToenges]

#Wearable device-based measures increasingly help to evaluate #Parkinsons symptoms including #gait, #balance for #PwP in #PD-MCT. Big thanks to all for a very nice collaboration of @ruhrunibochum and #Maetzler group from @NeurogeriatricK @kieluni. https://t.co/wfOylbScE7

[Lars Tönges @LarsToenges]

The pathophysiologic influence of #SARSCoV2 and #COVID19 for #Parkinsons remains an interesting topic with many unsolved questions. Please find our recent review with colleagues from @unidue and @ruhrunibochum @RUBMedizin now at @BrainSci_MDPI https://t.co/yZkAe0n7zc.

[Lars Tönges @LarsToenges]

Heute auf dem DPG Kongress #Parkinson und #Bewegungsstörungen @dpg_akbont. Individualisierte Therapie bei #Dystonie, #Huntington #Parkinson sowie #THS bei seltenen Bewegungsstörungen mit Kollegen von @unidue, @UniFreiburg und @ruhrunibochum @RUBMedizin https://t.co/gyncgHtJ0q

[Lars Tönges @LarsToenges]

Heute letzter Tag des DPG Kongresses #Parkinson und #Bewegungsstörungen @dpg_akbont. Gleich #Plenarsitzung Individualisierte Therapien mit Vorträgen über orale Pharmakotherapie, Medikamentenpumpen und Tiefenhirnstimulation. Please join ! https://t.co/gyncgHtJ0q

[Lars Tönges @LarsToenges]

#dpg2022 geht in 2 Tagen los ! Spannendes Programm zu #Parkinson und allen #bewegungsstoerungen. #PD @dgn_ev

[Dt. Kongress für Parkinson und Bewegungsstörungen @dpg_akbont]

Wir bieten Ihnen eine umfangreiche Posterausstellung - #AtypischeParkinsonSyndrome, #tiefeHirnstimulation, #Biomarker & #Pharmakotherapie.

Weitere Informationen finden Sie in unserem Online Programm: https://t.co/hDuQBcB1gs

#dpg2022 #akbont2022 #Parkinson #bewegungsstoerungen

[Dt. Kongress für Parkinson und Bewegungsstörungen @dpg_akbont]

Vom 24.-26. März 2022 befassen wir uns intensiver mit allen Themen rund um #Parkinson und #Bewegungsstörungen: #AtypischeParkinsonSyndrome, #KindlicheBewegungsstörungen und #Hirnstimulation.

Hier geht’s zum Online Programm: https://t.co/4WkbrISnzN

#dpg2022 #akbont2022

[Lars Tönges @LarsToenges]

Please check out our new #manuscript in @FrontiersIn about #Biomarkers in #Monogenetic Forms of # Parkinsons with Dr. Kwon @RUBMedizin and Prof. Klebe @unidue. Here, biomarkers such as #synuclein will be important for diagnostic / monitoring purposes, too.
https://t.co/GtvHRKVh60

[Lars Tönges @LarsToenges]

Very interesting Special Issue on #alphaSynuclein Amyloids & #Parkinsons Disease: On Growth, Spread, and Neurodegeneration https://t.co/wrFO0ipmRD #mdpibiomolecules via @Biomol_MDPI

[Lars Tönges @LarsToenges]

Please check out our new publication w O. Rascol in @ParkinsonismD on IR/ER #amantadine treatment in the #Parkinsons #ALLAY-LID studies. Robust anti #dyskinesia effect in #UDysRS scores and increased #ON time (!). Only moderate AE. https://t.co/G5C8c1779D

[Lars Tönges @LarsToenges]

New Update on #CSF #Biomarkers in #Parkinsons Disease in @Biomol_MDPI Special Issue in Honor of Prof. #Riederer. Is there more than #alpha-Synuclein and #NfL ?

https://t.co/IPXQM9R9pb

[Lars Tönges @LarsToenges]

Für alle an neurodegenerativen Erkrankungen, #Parkinson, #Demenz, #ALS Interessierten - 35 spannende Fälle aus der Praxis jetzt im neuen Fallbuch zusammen mit Dr. #Biesalski bei @SpringerNature !

https://t.co/vWzNPaks3Q

[Lars Tönges @LarsToenges]

#DGN2021 has started ! Please join, learn and exchange. First impressions are very good and stimulating !

[The Lancet @TheLancet]

NEW—Even for the #DeltaVariant, vaccine efficacy against severe #COVID19 so high that booster doses for general population are not appropriate at this stage in the pandemic.

Expert review of evidence to date by intl. group of scientists: https://t.co/3gytNuwrw9 #VaccinEquity

[Lars Tönges @LarsToenges]

Looking very much forward to #DGNKongress 2021 in November😀 @dgn_ev